[1] Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B. B.; Magliano, D. J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119.
[2] Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Committee, I. D. A. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Pract. 2019, 157, 107843.
[3] Khan, M. A. B.; Hashim, M. J.; King, J. K.; Govender, R. D.; Mustafa, H.; Al Kaabi, J. Epidemiology of type 2 diabetes–global burden of disease and forecasted trends. J. Epidemiol. Glob. Health 2020, 10, 107– 111.
[4] Prentki, M.; Nolan, C. J. Islet β cell failure in type 2 diabetes. J. Clin. Investig. 2006, 116, 1802–1812.
[5] Forbes, J. M.; Cooper, M. E. Mechanisms of diabetic complications. Physiol. Rev. 2013, 93, 137–188.
[6] Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270, 26746–26749.
[7] Hu, E.; Liang, P.; Spiegelman, B. M. AdipoQ is a movel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996, 271, 10697–10703.
[8] Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPoseMost abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 1996, 221, 286–289.
[9] Nakano, Y.; Tobe, T.; Choi-Miura, N. H.; Mazda, T.; Tomita, M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasm. J. Biochem. 1996, 120, 803–812.
[10] Mojiminiyi, O. A.; Abdella, N. A.; Al Arouj, M.; Ben Nakhi, A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int. J. Obes. (Lond.) 2007, 31, 213–220.
[11] Abdella, N. A.; Mojiminiyi, O. A. Clinical applications of adiponectin measurements in type 2 diabetes mellitus: screening, diagnosis, and marker of diabetes control. Dis. Markers 2018, 5187940.
[12] Kelesidis, I.; Kelesidis, T.; Mantzoros, C. Adiponectin and cancer: a systematic review. Br. J. Cancer 2006, 94, 1221–1225.
[13] Ouchi, N.; Walsh, K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta 2007, 380, 24–30.
[14] Han, S. H.; Quon, M. J.; Kim, J. A.; Koh, K. K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J. Am. Coll. Cardiol. 2007, 49, 531–538.
[15] Berg, A. H.; Combs, T. P.; Scherer, P. E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13, 84–89.
[16] Schraw, T.; Wang, Z. V.; Halberg, N.; Hawkins, M.; Scherer, P. E. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinology 2008, 149, 2270–2282.
[17] Swarbrick, M. M.; Havel, P. J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 2008, 6, 87–102.
[18] Chandran, M.; Phillips, S. A.; Ciaraldi, T.; Henry, R. R. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003, 26, 2442– 2450.
[19] Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mory, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M. L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7, 941–946.
[20] Antonopoulos, A. S.; Margaritis, M.; Coutinho, P.; Shirodaria, C.; Psarros, C.; Herdman, L.; Antoniades, C. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 2015, 64, 2207–2219.
[21] Berg, A. H.; Combs, T. P.; Du, X.; Brownlee, M.; Scherer, P. E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 2001, 7, 947–953.
[22] Fruebis, J.; Tsao, T. S.; Javorschi, S.; Ebbets-Reed, D.; Erickson, M. R. S.; Yen, F. T.; Bihain, B. E.; Lodish, H. F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2005–2010.
[23] Combs, T. P.; Pajvani, U. B.; Berg, A. H.; Lin, Y.; Jelicks, L. A.; Laplante, M.; Nawrocki, A. R.; Rajala, M. W.; Parlow, A. F.; Cheeseboro, L.; Ding, Y. Y.; Russell, R. G.; Lindemann, D.; Hartley, A.; Baker, G. R. C.; Obici, S.; Deshaies, Y.; Ludgate, M.; Rossetti, L.; Scherer, P. E. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145, 367–383.
[24] Maeda, N.; Shimomura, I.; Kishida, K.; Nishizawa, H.; Matsuda, M.; Nagaretani, H.; Furuyama, N.; Kondo, H.; Takahashi, M.; Arita, Y.; Komuro, R.; Ouchi, N.; Kihara, S.; Tochino, Y.; Okutomi, K.; Horie, M.; Takeda, S.; Aoyama, T.; Funahashi, T.; Matsuzawa, Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8, 731–737.
[25] Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N. H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423, 762–769.
[26] Kadowaki, T.; Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 26, 439–451.
[27] Mao, X.; Kikani, C. K.; Riojas, R. A.; Langlais, P.; Wang, L.; Ramos, F. J.; Fang, Q.; Christ-Roberts, C. Y.; Hong, J. Y.; Kim, R. Y.; Liu, F.; Dong, L. Q. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat. Cell Biol. 2006, 8, 516–523.
[28] Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; Eto, K.; Akanuma, Y.; Froguel, P.; Foufelle, F.; Ferre, P.; Carling, D.; Kimura, S.; Nagai, R.; Kahn, B. B.; Kadowaki, T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8, 1288–1295.
[29] Viollet, B.; Foretz, M.; Guigas, B.; Horman, S.; Dentin, R.; Bertrand, L.; Hue, L.; Andreelli, F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. Paris 2006, 574, 41–53.
[30] Sanz, P. AMP-activated protein kinase: structure and regulation. Curr. Protein Pept. Sci. 2008, 9, 478–492.
[31] Fullerton, M. D.; Galic, S.; Marcinko, K.; Sikkema, S.; Pulinilkunnil, T.; Chen, Z. P.; O'Neill, H. M.; Ford, R. J.; Palanivel, R.; O'Brien, M.; Hardie, D. G.; Macaulay, S. L.; Schertzer, J. D.; Dyck, J. R. B.; Denderen, B. J. V.; Van, B. J.; Kemp, B. E.; Steinberg, G. R. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 2013, 19, 1649–1654.
[32] Ceddia, R. B.; Somwar, R.; Maida, A.; Fang, X.; Bikopoulos, G.; Sweeney, G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005, 48, 132–139.
[33] Vu, V.; Bui, P.; Eguchi, M.; Xu, A.; Sweeney, G. Globular adiponectin induces LKB1/AMPK-dependent glucose uptake via actin cytoskeleton remodeling. J. Mol. Endocrinol. 2013, 51, 155–165.
[34] Civitarese, A. E.; Ukropcova, B.; Carling, S.; Hulver, M.; DeFronzo, R. A.; Mandarino, L.; Ravussin, E.; Smith, S. R. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab. 2006, 4, 75–87.
[35] Andreelli, F.; Foretz, M.; Knauf, C.; Cani, P. D.; Perrin, C.; Iglesias, M. A.; Pillot, B.; Bado, A.; Tronche, F.; Mithieux, G.; Vaulont, S.; Burcelin, R.; Viollet, B. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006, 147, 2432–2441.
[36] Otvos Jr, L. Potential adiponectin receptor response modifier therapeutics. Front. Endocrinol. 2019, 10, 539.
[37] Hossain, M. M.; Mukheem, A.; Kamarul, T. The prevention and treatment of hypoadiponectinemia-associated human diseases by up- regulation of plasma adiponectin. Life Sci. 2015, 135, 55–67.
[38] Otvos, L.; Haspinger, E.; La Russa, F.; Maspero, F.; Graziano, P.; Kovalszky, I.; Cassone, M. Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 2011, 11, 90.
[39] Sayeed, M.; Gautam, S.; Verma, D. P.; Afshan, T.; Kumari, T.; Srivastava, A. K.; Ghosh, J. K. A collagen domain–derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms. J. Biol. Chem. 2018, 293, 13509–13523.
[40] Ma, L.; Zhang, Z.; Xue, X.; Wan, Y.; Ye, B.; Lin, K. A potent peptide as adiponectin receptor 1 agonist to against fibrosis. J. Enzyme Inhib. Med. Chem. 2017, 32, 624–631.
[41] Kim, S.; Lee, Y.; Kim, J. W.; Son, Y. J.; Ma, M. J.; Um, J. H.; Kim, N. D.; Min, S. H.; Kim, D. I.; Kim, B. B. Discovery of a novel potent peptide agonist to adiponectin receptor 1. PLoS One 2018, 13, e0199256.
[42] Okada-Iwabu, M.; Yamauchi, T.; Iwabu, M.; Honma, T.; Hamagami, K.; Matsuda, K.; Yamaguchi, M.; Tanabe, H.; Kimura-Someya, T.; Shirouzu, M.; Ogata, H.; Tokuyama, K.; Ueki, K.; Nagano, T.; Tanaka, A.; Yokoyama, S.; Kadowaki, T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503, 493–499.
[43] Zhang, Y.; Zhao, J.; Li, R.; Lau, W. B.; Yuan, Y. X.; Liang, B.; Li, R.; Gao, E. H.; Koch, W. J.; Ma, X. L.; Wang, Y. J. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am. J. Physiol. - Endocrinol. Metab. 2015, 309, E275–E282.
[44] Ramzan, A. A.; Bitler, B. G.; Hicks, D.; Barner, K.; Qamar, L.; Behbakht, K.; Powell, T.; Jansson, T.; Wilson, H. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol. Cell. Biochem. 2019, 461, 37–46.
[45] Nicolas, S.; Debayle, D.; Béchade, C.; Maroteaux, L.; Gay, A. S.; Bayer, P.; Heurteaux, C.; Guyon, A.; Chabry, J. Adiporon, an adiponectin receptor agonist acts as an antidepressant and metabolic regulator in a mouse model of depression. Transl. Psychiatry 2018, 8, 1–11.
[46] Wang, Y.; Wan, Y.; Ye, G.; Wang, P.; Xue, X.; Wu, G.; Ye, B. Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice. Eur. J. Pharm. Sci . 2016, 93, 123–131.
[47] Zheng, J.; Sun, Z.; Liang, F.; Xu, W.; Lu, J.; Shi, L.; Shao, A.; Yu, J.; Zhang, J. AdipoRon attenuates neuroinflammation after intracerebral hemorrhage through AdipoR1-AMPK pathway. Neuroscience 2019, 412.
[48] Mine, Y.; Matsui, T. Current understanding of bioaccessibility and bioavailability of food‐derived bioactive peptides. Int. J. Food Sci. Technol. 2019, 54, 2319–2320.
[49] Korhonen, H.; Pihlanto, A. Food-derived bioactive peptides-opportunities for designing future foods. Curr. Pharm. Des. 2003, 9, 1297–1308.
[50] Xu, Q.; Yan, X.; Zhang, Y.; Wu, J. Current understanding of transport and bioavailability of bioactive peptides derived from dairy proteins: a review. Int. J. Food Sci. 2019, 54, 1930–1941.
[51] Miner-Williams, W. M.; Stevens, B. R.; Moughan, P. J. Are intact peptides absorbed from the healthy gut in the adult human? Nutr. Res. Rev. 2014, 27, 308–329.
[52] Matsui, T.; Sato, M.; Tanaka, M.; Yamada, Y.; Watanabe, S.; Fujimoto, Y.; Imaizumi, K.; Matsumoto, K. Vasodilating dipeptide Trp-His can prevent atherosclerosis in apo E-deficient mice. Br. J. Nutr. 2010, 103, 309–313.
[53] Matsui, T.; Tamaya, K.; Seki, E.; Osajima, K.; Matsumoto, K.; Kawasaki, T. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin. Exp. Pharmacol. Physiol. 2002, 29, 204–208.
[54] Tanaka, M.; Hong, S. M.; Akiyama, S.; Hu, Q. Q.; Matsui, T. Visualized absorption of anti‐atherosclerotic dipeptide, Trp‐His, in Sprague– Dawley rats by LC‐MS and MALDI‐MS imaging analyses. Mol. Nutr. Food Res. 2015, 59, 1541–1549.
[55] Hong, S. M.; Tanaka, M.; Yoshii, S.; Mine, Y.; Matsui, T. Enhanced visualization of small peptides absorbed in rat small intestine by phytic- acid-aided matrix-assisted laser desorption/ionization-imaging mass spectrometry. Anal. Chem. 2013, 85, 10033–10039.
[56] Tanaka, M.; Dohgu, S.; Komabayashi, G.; Kiyohara, H.; Takata, F.; Kataoka, Y.; Nirasawa, T.; Maebuchi, M.; Matsui, T. Brain-transportable dipeptides across the blood-brain barrier in mice. Sci. Rep. 2019, 9, 1– 10.
[57] Tanaka, M.; Kiyohara, H.; Yoshino, A.; Nakano, A.; Takata, F.; Dohgu, S.; Kataoka, Y.; Matsui, T. Brain-transportable soy dipeptide, Tyr-Pro, attenuates amyloid β peptide25-35-induced memory impairment in mice. npj Sci. Food. 2020, 4, 1–4.
[58] Nakamura, Y.; Yamamoto, N.; Sakai, K.; Takano, T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. Int. J. Dairy Sci. 1995, 78, 1253–1257.
[59] Vanhoof, G.; Goossens, F.; De Meester, I.; Hendriks, D.; Scharpé, S. Proline motifs in peptides and their biological processing. FASEB J. 1995, 9, 736–744.
[60] Soga, M.; Ohashi, A.; Taniguchi, M.; Matsui, T.; Tsuda, T. The di-peptide Trp-His activates AMP-activated protein kinase and enhances glucose uptake independently of insulin in L6 myotubes. FEBS Open Bio 2014, 4, 898–904.
[61] Kobayashi, Y.; Kovacs-Nolan, J.; Matsui, T.; Mine, Y. The anti- atherosclerotic dipeptide, Trp-His, reduces intestinal inflammation through the blockade of L-type Ca2+ channels. J. Agric. Food Chem. 2015, 63, 6041–6050.
[62] Matsui, T.; Ueno, T.; Tanaka, M.; Oka, H.; Miyamoto, T.; Osajima, K.; Matsumoto, K. Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells. Hypertens. Res. 2005, 28, 545– 552.
[63] Okamoto, K.; Kawamura, S.; Tagawa, M.; Mizuta, T.; Zahid, H. M.; Nabika, T. Production of an antihypertensive peptide from milk by the brown rot fungus Neolentinus lepideus. Eur. Food Res. 2020, 246, 1773– 1782.
[64] Neves, A. C.; Harnedy, P. A.; O’Keeffe, M. B.; FitzGerald, R. J. Bioactive peptides from Atlantic salmon (Salmo salar) with angiotensin converting enzyme and dipeptidyl peptidase IV inhibitory, and antioxidant activities. Food Chem. 2017, 218, 396–405.
[65] Nakamura, T.; Hirota, T.; Mizushima, K.; Ohki, K.; Naito, Y.; Yamamoto, N.; Yoshikawa, T. Milk-derived peptides, Val-Pro-Pro and Ile-Pro-Pro, attenuate atherosclerosis development in apolipoprotein E–deficient mice: a preliminary study. J. Med. Food 2013, 16, 396–403.
[66] Liao, W.; Fan, H.; Davidge, S. T.; Wu, J. Egg white–derived antihypertensive peptide IRW (Ile‐Arg‐Trp) reduces blood pressure in spontaneously hypertensive rats via the ACE2/ang (1‐7)/mas receptor Axis. Mol. Nutr. Food Res. 2019, 63, 1900063.
[67] Son, M.; Chan, C. B.; Wu, J. Egg white ovotransferrin‐derived ACE inhibitory peptide ameliorates angiotensin II‐stimulated insulin resistance in skeletal muscle cells. Mol. Nutr. Food Res. 2018, 62, 1700602.
[68] Jiao, H.; Zhang, Q.; Lin, Y.; Gao, Y.; Zhang, P. The ovotransferrin- derived peptide IRW attenuates lipopolysaccharide-induced inflammatory responses. Biomed Res. Int. 2019, 2019.
[69] Kovacs-Nolan, J. M.; Zhang, H.; Ibuki, M.; Nakamori, T.; Yoshiura, K.; Turner, P. V.; Matsui, T.; Mine, Y. The PepT1-transportable soy tripeptide VPY reduces intestinal inflammation. Biochim. Biophys. Acta. Gen. Subj. 2012, 1820, 1753–1763.
[70] Merz, K. E.; Thurmond, D. C. Role of skeletal muscle in insulin resistance and glucose uptake. Compr. Physiol. 2011, 10, 785–809.
[71] Wijesekara, N.; Thong, F. S.; Antonescu, C. N.; Klip, A. Diverse signals regulate glucose uptake into skeletal muscle. Can. J. Diabetes 2006, 30, 80–88.
[72] Qiu, J.; Maekawa, K.; Kitamura, Y.; Miyata, Y.; Tanaka, K.; Tanaka, T.; Soga, M.; Tsuda, T.; Matsui, T. Stimulation of glucose uptake by theasinensins through the AMP-activated protein kinase pathway in rat skeletal muscle cells. Biochem. Pharmacol. 2014, 87, 344–351.
[73] Liu, L.; Zheng, J.; Zhou, M.; Li, S.; He, G.; Wu, J. Peptide analogues of VPP and IPP with improved glucose uptake activity in L6 myotubes can be released from cereal proteins. J. Agric. Food Chem. 2021, 69, 2875– 2883.
[74] Iwasa, M.; Takezoe, S.; Kitaura, N.; Sutani, T.; Miyazaki, H.; Aoi, W. A milk casein hydrolysate‐derived peptide enhances glucose uptake through the AMP‐activated protein kinase signalling pathway in skeletal muscle cells. Exp. Physiol. 2021, 106, 496–505.
[75] Straub, L. G.; Scherer, P. E. Metabolic messengers: adiponectin. Nat. Metab. 2019, 3, 334–339.
[76] Choi, S. R.; Lim, J. H.; Kim, M. Y.; Kim, E. N.; Kim, Y.; Choi, B. S.; Park, C. W. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. Metab.: Clin. Exp. 2018, 85, 348–360.
[77] Choi, S. K.; Kwon, Y.; Byeon, S.; Haam, C. E.; Lee, Y. H. AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice. PLoS One 2020, 15, e0230227.
[78] Zou, C.; Wang, Y.; Shen, Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J. Biochem. Biophys. methods 2005, 64, 207–215.
[79] Nishiumi, S.; Ashida, H. Rapid preparation of a plasma membrane fraction from adipocytes and muscle cells: application to detection of translocated glucose transporter 4 on the plasma membrane. Biosci. Biotechnol. Biochem. 2007, 71, 2343–2346.
[80] Jo, S.; Kim, T.; Iyer, V. G.; Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 2008, 29, 1859–1865.
[81] Boonstra, S.; Onck, P. R.; van der Giessen, E. CHARMM TIP3P water model suppresses peptide folding by solvating the unfolded state. J. Phys. Chem. B 2016, 120, 3692–3698.
[82] Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.; Simmerling, C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 2015, 11, 3696–3713.
[83] Dickson, C. J.; Madej, B. D.; Skjevik, Å. A.; Betz, R. M.; Teigen, K.; Gould, I. R.; Walker, R. C. Lipid14: the amber lipid force field. J. Chem. Theory Comput. 2014, 10, 865–879.
[84] Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, 1157–1174.
[85] Case, D. A.; Cheatham III, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz Jr, K. M.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs. J. Comput. Chem. 2005, 26, 1668–1688.
[86] Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33, 889–897.
[87] Miyagusuku-Cruzado, G.; Morishita, N.; Fukui, K.; Terahara, N.; Matsui, T. Anti-prediabetic effect of 6-O-caffeoylsophorose in prediabetic rats and its stimulation of glucose uptake in L6 myotubes. Food Sci. Technol. Res. 2017, 23, 449–456.
[88] Vlavcheski, F.; Naimi, M.; Murphy, B.; Hudlicky, T.; Tsiani, E. Rosmarinic acid, a rosemary extract polyphenol, increases skeletal muscle cell glucose uptake and activates AMPK. Molecules 2017, 22, 1669.
[89] Zygmunt, K.; Faubert, B.; MacNeil, J.; Tsiani, E. Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK. Biochem. Biophys. Res. Commun. 2010, 398, 178–183.
[90] Rodríguez, Y.; Májeková, M. Structural Changes of Sarco/Endoplasmic Reticulum Ca2+-ATPase Induced by Rutin Arachidonate: A Molecular Dynamics Study. Biomolecules 2020, 10, 214.
[91] Banerjee, S.; Talukdar, I.; Banerjee, A.; Gupta, A.; Balaji, A.; Aduri, R. Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments. J. Biosci. 2019, 44, 1–13.
[92] Patil, P.; Mandal, S.; Tomar, S. K.; Anand, S. Food protein-derived bioactive peptides in management of type 2 diabetes. Eur. J. Nutr. 2015, 54, 863–880.
[93] C de Campos Zani, S.; Wu, J.; B Chan, C. Egg and soy-derived peptides and hydrolysates: A review of their physiological actions against diabetes and obesity. Nutrients 2018, 10, 549.
[94] Azadbakht, L.; Atabak, S.; Esmaillzadeh, A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care 2008, 31, 648–654.
[95] Hansen, P. R.; Oddo, A. Fmoc solid-phase peptide synthesis. Methods Mol. Biol. 2015, 1348, 33–50.
[96] Hanh, V. T.; Kobayashi, Y.; Maebuchi, M.; Nakamori, T.; Tanaka, M.; Matsui, T. Quantitative mass spectrometric analysis of dipeptides in protein hydrolysate by a TNBS derivatization-aided standard addition method. Food Chem. 2016, 190, 345–350.
[97] Kumari, R.; Kumar, R. g_mmpbsa–A GROMACS tool for high- throughput MM-PBSA calculations. J. Chem. Inf. Model. 2014, 54, 1951–1962.
[98] Samoto, M.; Maebuchi, M.; Miyazaki, C.; Kugitani, H.; Kohno, M.; Hirotsuka, M.; Kito, M. Abundant proteins associated with lecithin in soy protein isolate. Food Chem. 2007, 102, 317–322.
[99] Kim, E. D.; Bayaraa, T.; Shin, E. J.; Hyun, C. K. Fibroin-derived peptides stimulate glucose transport in normal and insulin-resistant 3T3-L1 adipocytes. Biol. Pharm. Bull 2009, 32, 427–433.
論文の公開元へ
